157435-10-4|XK469|2-(4-((7-chloroquinoxalin-2-yl)oxy)phenoxy)propanoic acid|-范德生物科技公司

XK469

NMR下载 COA and HPLC MSDS下载
names：
2-(4-((7-chloroquinoxalin-2-yl)oxy)phenoxy)propanoic acid
CAS号：
157435-10-4
MDL Number：
MF(分子式)： C17H13ClN2O4 MW(分子量)： 344.74912
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	2-(4-((7-chloroquinoxalin-2-yl)oxy)phenoxy)propanoic acid
英文别名	XK469; XK 469; XK-469; NSC697887; NSC-697887; NSC 697887.
CAS号	157435-10-4
SMILES	CC(OC1=CC=C(OC2=NC3=CC(Cl)=CC=C3N=C2)C=C1)C(O)=O
Inchi	InChI=1S/C17H13ClN2O4/c1-10(17(21)22)23-12-3-5-13(6-4-12)24-16-9-19-14-7-2-11(18)8-15(14)20-16/h2-10H,1H3,(H,21,22)
InchiKey	NUQZXROIVGBRGR-UHFFFAOYSA-N
分子式 Formula	C17H13ClN2O4
分子量 Molecular Weight	344.74912
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	XK469(CAS:157435-10-4 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	XK489 is a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kakodkar NC, Peddinti R, Kletzel M, Tian Y, Guerrero LJ, Undevia SD, Geary D, Chlenski A, Yang Q, Salwen HR, Cohn SL. The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatr Blood Cancer. 2011 Jan;56(1):164-7. doi: 10.1002/pbc.22639. PubMed PMID: 20860039.

[2]Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer. 2009 Jul;45(11):1904-8. doi: 10.1016/j.ejca.2009.04.032. Epub 2009 May 21. PubMed PMID: 19464879; PubMed Central PMCID: PMC2758059.

[3] Reiners JJ Jr, Kleinman M, Joiakim A, Mathieu PA. The chemotherapeutic agents XK469 (2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid) and SH80 (2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid) inhibit cytokinesis and promote polyploidy and induce senescence. J Pharmacol Exp Ther. 2009 Mar;328(3):796-806. doi: 10.1124/jpet.108.144808. Epub 2008 Dec 9. PubMed PMID: 19066341; PubMed Central PMCID: PMC2682258.

[4] Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug;44(12):1684-92. doi: 10.1016/j.ejca.2008.05.018. Epub 2008 Jul 21. PubMed PMID: 18650079; PubMed Central PMCID: PMC2731567.

[5] Kessel D, Reiners JJ Jr, Hazeldine ST, Polin L, Horwitz JP. The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80. Mol Cancer Ther. 2007 Jan;6(1):370-9. PubMed PMID: 17237296; PubMed Central PMCID: PMC2877038.

6: Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs. 2007 Apr;25(2):147-54. Epub 2006 Nov 11. PubMed PMID: 17103044.7: Hazeldine ST, Polin L, Kushner J, White K, Corbett TH, Horwitz JP. Synthesis and biological evaluation of conformationally constrained analogs of the antitumor agents XK469 and SH80. Part 5. Bioorg Med Chem. 2006 Apr 1;14(7):2462-7. Epub 2005 Dec 5. PubMed PMID: 16337128.8: Hazeldine ST, Polin L, Kushner J, White K, Corbett TH, Horwitz JP. Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4. Bioorg Med Chem. 2005 Jun 2;13(12):3910-20. PubMed PMID: 15911307.9: Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, Ivy SP. Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemother Pharmacol. 2005 Oct;56(4):351-7. Epub 2005 May 13. PubMed PMID: 15895233.10: Boinpally RR, Zhou SL, LoRusso PM, Parchment RE. Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration. Cancer Chemother Pharmacol. 2005 Apr;55(4):404-7. Epub 2004 Dec 9. PubMed PMID: 15592839.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开